Carilex Medical, Inc (7726) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Carilex Medical, Inc stock TWD 27.66, price TWD 32.15, that is 14.0% below the price, quality 36 out of 100. Rating: overvalued. Calculated from audited financials with 7 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
11‑month range 30.70 TWD – 41.90 TWD · fair‑value band 22.47 TWD – 34.86 TWD · the 32.15 TWD price screens above the 27.66 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Carilex Medical in your weekly email
Every Wednesday you see whether Carilex Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Carilex Medical, Inc. engages in the research and development, manufacture, and sale of medical devices for wound care management worldwide. It offers support surfaces, chair cushions, and negative pressure wound therapy products to prevent and manage pressure sores and wounds.
Show moreShow less
The company was founded in 1985 and is headquartered in Taoyuan City, Taiwan.
Stock analysis
Carilex Medical, Inc (7726) currently trades at 32.15 TWD, while our model-based Fair Value estimate is 27.66 TWD, 14% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 33.23 TWD per share, and 4 of the 7 models we run sit above the 32.15 TWD price.
Bear case: the Asset-Based group reads lowest at 9.32 TWD, and 3 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 22.47 TWD (bear) to 34.86 TWD (bull), the price of 32.15 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak: less than 2 % a year.
Carilex Medical, Inc reported revenue of 339M TWD in FY2025 versus 388M TWD in FY2021, a compound −3.3%/yr. Reported net income was −29.0M TWD in FY2025.
Key figures
Market cap 653M TWD (≈ $19.9M) Micro · EPS (TTM) −0.6200 TWD · Net margin −8.6% · Return on assets (EBIT) 3.9% (5-year average) · Free cash flow 36.0M TWD · Net cash 65.2M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (medium confidence).
What moves the price
The share trades about 23% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −14%, 7726 screens cheaper than that median.
Fair Value models
Bear22.47 TWDFair Value 27.66 TWDBull34.86 TWD
Price 32.15 TWD · Downside -14.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF27.20 TWD32.54 TWD41.76 TWD80
Growth DCF27.80 TWD32.89 TWD41.01 TWD77
5Y Revenue Exit26.43 TWD33.16 TWD42.95 TWD71
All 7 models by family
DCF Models
FCF DCF27.20 TWD32.54 TWD41.76 TWD80
5Y Revenue Exit26.43 TWD33.16 TWD42.95 TWD71
10Y Revenue Exit26.27 TWD31.09 TWD36.22 TWD66
Multiples
EV/Revenue19.37 TWD26.29 TWD33.21 TWD51
Asset-Based
NCAV (Graham)6.15 TWD9.32 TWD11.65 TWD52
Growth DCF
Growth DCF27.80 TWD32.89 TWD41.01 TWD77
Rev-Margin DCF26.43 TWD33.57 TWD42.36 TWD71
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.27/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
21.0% (2020) → −12.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +7.2% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 320 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Bottom 25%
Fair Value upside−14.0% · Above median
Profitability
Return on assets−5.4% · Below median
Net margin (12 months)−8.6% · Below median
Operating margin (12 months)0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)0.0% · Below median
Dividend yield (12 months)0.0% · Bottom 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Carilex Medical, Inc (7726) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of 27.66 TWD versus a price of 32.15 TWD, about 14% lower (overvalued).
What is the fair value of 7726?
Our model-based fair value for Carilex Medical, Inc is 27.66 TWD (as of Nov 7, 2026), built from audited fundamentals. The current price: 32.15 TWD.
What is the quality score of 7726?
Carilex Medical, Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Carilex Medical, Inc (7726)?
Our model-based price target is the fair value of 27.66 TWD (as of Nov 7, 2026) from 7 valuation models. Cautious scenario 22.47 TWD, optimistic scenario 34.86 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Carilex Medical, Inc stock forecast for 2026?
Our models put fair value at 27.66 TWD, about 14% lower versus a price of 32.15 TWD (overvalued). Cautious scenario 22.47 TWD, optimistic scenario 34.86 TWD. The calculation is refreshed regularly with new filings.
What growth is priced into Carilex Medical, Inc (7726)?
For today's price to be fair in a discounted-cash-flow model, Carilex Medical, Inc would have to grow free cash flow by +8.9 % per year for five years (discount rate 10.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -0.5 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of 7726 use?
Our models discount Carilex Medical, Inc at 10.3 %: a base by market capitalisation (nano), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Carilex Medical, Inc that is +8.9 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.3 %) and the same formula as our fair value.
How much growth has Carilex Medical, Inc (7726) delivered so far?
Over the past 5 years revenue at Carilex Medical, Inc grew -0.5 % a year. The price currently implies free-cash-flow growth of +8.9 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Carilex Medical, Inc (7726) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into Carilex Medical, Inc (+8.9 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Carilex Medical, Inc (7726)?
The free-cash-flow yield on the price is 5.52 %: that much free cash flow Carilex Medical, Inc produces per unit of market value. When it exceeds the discount rate of our models (10.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Carilex Medical, Inc (7726)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Carilex Medical, Inc it is 27.66 TWD per share (as of Nov 7, 2026), against a price of 32.15 TWD. It is the blended result of 7 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Carilex Medical, Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, 7726 trades above its calculated fair value: price 32.15 TWD, fair value 27.66 TWD, a gap of about −14% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 7726?
No. The price is what the market pays today (32.15 TWD); the fair value is what the company's own numbers justify (27.66 TWD). For Carilex Medical, Inc the two are 4.49 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Carilex Medical, Inc worth?
The market values Carilex Medical, Inc at about 653M TWD (market capitalisation, as of Nov 7, 2026). Per share that is 32.15 TWD; our models calculate a fair value of 27.66 TWD per share.
What do the bullish and bearish scenarios say about 7726?
Our models span a range for Carilex Medical, Inc: cautious scenario 22.47 TWD, base 27.66 TWD, optimistic 34.86 TWD per share (as of Nov 7, 2026, price 32.15 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 7726 from its 52-week high?
Carilex Medical, Inc trades at 32.15 TWD, about 23% below its 52-week high of 41.90 TWD and 5% above the low of 30.70 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 27.66 TWD is for.
Which stocks are comparable to Carilex Medical, Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Carilex Medical, Inc stock attractive at the current price?
The data as of Nov 7, 2026: price 32.15 TWD, calculated fair value 27.66 TWD (−14%), Quality Score 36/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 7726 calculated?
We run Carilex Medical, Inc through 7 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of 27.66 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Carilex Medical, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Carilex Medical, Inc (7726)?
The closing price on Nov 9, 2026 was 32.15 TWD. Our model-based fair value is 27.66 TWD, about 14% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Carilex Medical, Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Carilex Medical, Inc
How large is the market capitalisation of Carilex Medical, Inc (7726)?
The market capitalisation of Carilex Medical, Inc is 653M TWD (≈ $19.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Carilex Medical, Inc (7726)?
Earnings per share at Carilex Medical, Inc are −0.6200 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Carilex Medical, Inc (7726)?
The net margin of Carilex Medical, Inc is −8.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Carilex Medical, Inc (7726)?
On an EBIT basis the return on assets of Carilex Medical, Inc is 3.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net cash does Carilex Medical, Inc (7726) hold?
Carilex Medical, Inc holds more cash than debt, 65.2M TWD net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Carilex Medical, Inc in the live analysis
One click puts Carilex Medical, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 7, 2026